Background and Purpose—No controlled, randomized trial has investigated whether intravenous, intra-arterial (IAT), or mechanical thrombolysis is beneficial in children with ischemic stroke. We report 2 children who underwent IAT for acute ischemic stroke and include them in a review about intravenous thrombolysis, IAT, and mechanical thrombolysis for childhood stroke. Methods—We searched in MED...

The science of metric-based patient stratification for intravenous thrombolysis, revolutionized by the landmark National Institute of Neurological Disorders and Stroke trial, has transformed acute ischaemic stroke therapy. Recanalization of an occluded artery produces tissue reperfusion that unequivocally improves outcome and function in patients with acute ischaemic stroke. Recanalization can ...

In a prospective study, nine patients with phlegmasia caerulea dolens (PCD) related to iliac occlusive thrombosis were treated with intravenous thrombolysis. After thrombolysis, despite no significant improvement in the Marder score value, progression to venous gangrene, major hemorrhage or death was not observed and no amputation was needed. Intravenous thrombolysis should be seriously conside...

Objective: To compare the therapeutic effects of intravenous alteplase thrombolysis, intravenous urokinase thrombolysis and interventional urokinase thrombolysis for acute ischemic stroke. Methods: One hundred and twenty patients of acute ischemic stroke who were treated in our hospital from January 2015 to January 2017 were selected and separated into intravenous alteplase thrombolytic treatme...

BACKGROUND AND PURPOSE It is important to know the costs for hospitalization for ischemic stroke patients treated with intravenous thrombolysis so that comparisons can be made with payments to hospitals. METHODS Using the National Inpatient Sample, we evaluated hospitalization costs for patients treated with intravenous thrombolysis for acute ischemic stroke in the United States from 2001 to ...

Intravenous thrombolysis with recombinant tissue plasminogen activator is the standard of care for the treatment of acute ischemic stroke within 3 hours after stroke onset. Randomized clinical studies have demonstrated that intravenous thrombolysis improves functional outcomes but is not lifesaving. Complications of intravenous thrombolysis include severe intracranial hemorrhage that may be let...

Acute ischemic stroke is a major cause of morbidity and mortality in Europe, North America, and Asia. Its treatment has completely changed over the past decade with different interventional approaches, such as intravenous trials, intra-arterial trials, combined intravenous/intra-arterial trials, and newer devices to mechanically remove the clot from intracranial arteries. Intravenous thrombolys...

Coronary thrombolysis was induced by infusion of highly purified human pro-urokinase isolated from a transformed kidney cell line (ACHN) or by infusion of urokinase of urinary origin in anesthetized dogs with 1-hr-old clots in the left anterior descending coronary artery. The clots were induced with a copper coil and thrombolysis was detected by repeat coronary angiography. Intravenous infusion...

The most effective medical treatment for acute ischaemic stroke (AIS) is to offer intravenous thrombolysis during the ultra-early period of time after the onset. Even based on the Consensus of Chinese Experts on Intravenous Thrombolysis for AIS in 2012 and 2014 Chinese Guidelines on the Diagnosis and Treatment of AIS, the rate of thrombolysis for AIS in China remained around 2.4%, and the rate ...

In the article by Spaander et al, “‘Sex Differences and Functional Outcome After Intravenous Thrombolysis,” which published online ahead of print January 31, 2017, and appeared in the March 2017 issue of the journal (Stroke. 2017;48:699–703. DOI: 10.1161/STROKEAHA.116.014739), a correction is needed. On page 699, in the title, “‘Sex Differences and Functional Outcome After Intravenous Thromboly...